Alembic Stock/Share Prices, Buy and Sell Alembic BSE Stocks

Alembic Ltd NSE / BSE
Pharmaceuticals, Mid Cap

Invest

12 Dec 2018 | 03:59 PM

43.55

0.70 (1.63%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

-2.24%

Return (1Y)

Beaten S&P BSE Healthcare by 0.7%
More Volatile

3.02%

Standard Deviation (1Y)

Higher than S&P BSE Healthcare by 1.88%
Consistent Performer

7/12

Months

beaten S&P BSE Healthcare
AxisDirect View

No View

52 Week High-Low

News & Announcements

Alembic standalone net profit rises 4.00% in the September 2018 quarter
39 days ago

Alembic standalone net profit rises 4.00% in the September 2018 quarter

03 - Nov - 2018 12:00 AM | 39 days ago

Net profit of Alembic rose 4.00% to Rs 29.35 crore in the quarter ended September 2018 as against Rs 28.22 crore during the previous quarter ended September 2017. Sales rose 3.13% to Rs 33.56 crore in the quarter ended September 2018 as against Rs 32.54 crore during the previous quarter ended September 2017.
Particulars Quarter Ended
Sep. 2018 Sep. 2017 % Var.
Sales 33.56 32.54 3
OPM % 18.89 15.30 -
PBDT 30.52 30.88 -1
PBT 29.96 29.76 1
NP 29.35 28.22 4
Powered by Capital Market - Live News
Alembic to convene board meeting
49 days ago

Alembic to convene board meeting

24 - Oct - 2018 12:00 AM | 49 days ago

Alembic will hold a meeting of the Board of Directors of the Company on 30 October 2018.
Powered by Capital Market - Live News
Board of Alembic accords in-principle approval for scheme of arrangement
91 days ago

Board of Alembic accords in-principle approval for scheme of arrangement

11 - Sep - 2018 12:00 AM | 91 days ago

The Board of Alembic at its meeting held on 11 September 2018 has inter alia considered and accorded 'in-principle' approval to the proposal to demerge the Identified Real Estate Undertaking of the Company into Shreno, an unlisted public limited company, to be implemented by way of a Scheme of Arrangement.
The Identified Real Estate Undertaking proposed to be demerged would comprise of:
i) A premium residential real estate project of Alembic;
ii) Interest in real estate business held through investment in Shreno; and
iii) Project Management Consultancy ('PMC') business, services of which are provided by the Company to Shreno.
Powered by Capital Market - Live News
Alembic standalone net profit rises 106.27% in the June 2018 quarter
127 days ago

Alembic standalone net profit rises 106.27% in the June 2018 quarter

07 - Aug - 2018 12:00 AM | 127 days ago

Net profit of Alembic rose 106.27% to Rs 6.91 crore in the quarter ended June 2018 as against Rs 3.35 crore during the previous quarter ended June 2017. Sales rose 50.35% to Rs 44.52 crore in the quarter ended June 2018 as against Rs 29.61 crore during the previous quarter ended June 2017.
Particulars Quarter Ended
Jun. 2018 Jun. 2017 % Var.
Sales 44.52 29.61 50
OPM % 18.53 6.01 -
PBDT 9.49 5.59 70
PBT 8.85 4.36 103
NP 6.91 3.35 106
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

FII shareholding in Alembic Ltd has decreased by -8.31% since past 3 Months
MF shareholding in Alembic Ltd has increased by 7.1% since past 3 Months
FII shareholding in Alembic Ltd has decreased by -29.81% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Sep. 2018	Sep. 2017	% Var.
Sales	33.56	32.54	3
OPM %	18.89	15.30	-
PBDT	30.52	30.88	-1
PBT	29.96	29.76	1
NP	29.35	28.22	4

Particulars	Quarter Ended
	Jun. 2018	Jun. 2017	% Var.
Sales	44.52	29.61	50
OPM %	18.53	6.01	-
PBDT	9.49	5.59	70
PBT	8.85	4.36	103
NP	6.91	3.35	106

General Notifications

My Notifications

Research Notifications

Alembic Ltd NSE / BSE Pharmaceuticals, Mid Cap

43.55 0.70 (1.63%)

News & Announcements

Price vs Volume

Stock Trivia

Alembic Ltd NSE / BSE
Pharmaceuticals, Mid Cap

43.55

0.70 (1.63%)